New treatment option for Tarceva in Europe

Monday 22 March 2010

The European Medicines Agency is recommending that the cancer drug, Tarceva (erlotinib), be approved for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer. This represents a new treatment option.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom